Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Summary: Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting exp...
Main Author: | Jean-François Rossignol |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-05-01
|
Series: | Journal of Infection and Public Health |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1876034116300181 |
Similar Items
-
Treatment strategies for Middle East respiratory syndrome coronavirus
by: Kayvon Modjarrad
Published: (2016-01-01) -
A Pilot Clinical Trial of Nitazoxanide in the Treatment of Chronic Hepatitis B
by: Jean‐François Rossignol, et al.
Published: (2019-06-01) -
Emergence of the Middle East respiratory syndrome coronavirus.
by: Christopher M Coleman, et al.
Published: (2013-01-01) -
Middle East Respiratory Syndrome Coronavirus Transmission
by: Marie E. Killerby, et al.
Published: (2020-02-01) -
Novel Middle East respiratory syndrome coronavirus
by: Viroj Wiwanitkit
Published: (2014-01-01)